Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects

With the integration of nanotechnology into the medical field at large, great strides have been made in the development of nanome-dicines for tackling different diseases, including cancers. To date, various cancer nanomedicines have demonstrated success in pre -clinical studies, improving therapeutic outcomes, prolonging sur-vival, and/or decreasing side effects. However, the translation from bench to bedside remains challenging. While a number of nanomedicines have entered clinical trials, only a few have been approved for clinical applications. In this review, we highlight the most recent progress in cancer nanomedicine, discuss current clin-ical advances and challenges for the translation of cancer nanomedi-cines, and provide our viewpoints on accelerating clinical transla-tion. We expect this review to benefit the future development of cancer nanotherapeutics specifically from the clinical perspective.

Automated summary

With the integration of nanotechnology, significant progress has been made in developing nanomedicines for treating various diseases, including cancers. While many cancer nanomedicines have shown success in pre-clinical studies, the translation to clinical applications remains challenging. This review highlights recent advancements in cancer nanomedicine, discusses the current clinical progress and challenges, and provides insights for accelerating clinical translation.